AI Proteins Secures $41.5M Series A to Accelerate AI‑Driven Drug Discovery

Why It Matters

The sizable raise underscores growing investor confidence in AI‑enabled drug discovery, positioning AI Proteins to potentially shorten development timelines and capture market share in the competitive protein therapeutics space.

Deal Summary

Boston‑based AI Proteins announced a $41.5 million Series A round led by Mission BioCapital and Santé Ventures, with participation from Lightchain Capital, Cobro Ventures and other existing backers. The funding will be used to expand operations, boost R&D and advance its AI‑enabled protein therapeutics platform.